GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Goldenwell Biotech Inc (OTCPK:GWLL) » Definitions » Asset Turnover

Goldenwell Biotech (Goldenwell Biotech) Asset Turnover : 0.00 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Goldenwell Biotech Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Goldenwell Biotech's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Goldenwell Biotech's Total Assets for the quarter that ended in Mar. 2024 was $0.21 Mil. Therefore, Goldenwell Biotech's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Goldenwell Biotech's annualized ROE % for the quarter that ended in Mar. 2024 was -178.42%. It is also linked to ROA % through Du Pont Formula. Goldenwell Biotech's annualized ROA % for the quarter that ended in Mar. 2024 was -58.08%.


Goldenwell Biotech Asset Turnover Historical Data

The historical data trend for Goldenwell Biotech's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Goldenwell Biotech Asset Turnover Chart

Goldenwell Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Asset Turnover
- 0.05 0.14 0.01

Goldenwell Biotech Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Goldenwell Biotech's Asset Turnover

For the Packaged Foods subindustry, Goldenwell Biotech's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Goldenwell Biotech's Asset Turnover Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Goldenwell Biotech's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Goldenwell Biotech's Asset Turnover falls into.



Goldenwell Biotech Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Goldenwell Biotech's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0.002/( (0.248+0.228)/ 2 )
=0.002/0.238
=0.01

Goldenwell Biotech's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=0/( (0.228+0.199)/ 2 )
=0/0.2135
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Goldenwell Biotech  (OTCPK:GWLL) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Goldenwell Biotech's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-0.124/0.0695
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-0.124 / 0)*(0 / 0.2135)*(0.2135/ 0.0695)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*3.0719
=ROA %*Equity Multiplier
=-58.08 %*3.0719
=-178.42 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Goldenwell Biotech's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-0.124/0.2135
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-0.124 / 0)*(0 / 0.2135)
=Net Margin %*Asset Turnover
= %*0
=-58.08 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Goldenwell Biotech Asset Turnover Related Terms

Thank you for viewing the detailed overview of Goldenwell Biotech's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Goldenwell Biotech (Goldenwell Biotech) Business Description

Traded in Other Exchanges
N/A
Address
2071 Midway Drive, Twinsburg, OH, USA, 44087
Goldenwell Biotech Inc is engaged in the research and development, production and sales of health care and supplements products. Its products comprise JI MAI - Bovine Cardiac Vascular Active Peptide, Double Proline AG - 3D Active Collagen Peptide, Cartilage Peptide - Type II collagen peptide, and Sugar Master.
Executives
Li Yang director, 10 percent owner, officer: Treasurer C/O GOLDENWELL BIOTECH, INC., 2071 MIDWAY DRIVE, TWINSBURG OH 44087
Hua Xie director, officer: Secretary C/O GOLDENWELL BIOTECH, INC., 2071 MIDWAY DRIVE, TWINSBURG OH 44087
Shuang Liu director, 10 percent owner, officer: Chief Executive Officer C/O GOLDENWELL BIOTECH, INC., 2071 MIDWAY DRIVE, TWINSBURG OH 44087

Goldenwell Biotech (Goldenwell Biotech) Headlines

No Headlines